Jan Burger, MD, PhD, from the MD Anderson Cancer Center, Houston, TX, discusses the importance of patient-physician communication. He highlights the cruciality of keeping patients with chronic lymphocytic leukemia (CLL) who are treated with novel immunotherapeutic agents, informed as to why their leukemic cell count will initially rise and how this is not a bad sign as many patients may be concerned with this occurrence. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.